– USA, VA – Landos Biopharma, Inc. (NASDAQ: LABP), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today announced the appointment of Dr. Alka Batycky (Ph.D.) to its Board of Directors, bringing with her over 25 years of global drug development experience in the biopharmaceutical industry, spanning from early discovery through product approval across a broad range of therapeutic areas.
“Dr. Batycky is an accomplished biopharmaceutical executive and an important addition to Landos’ Board. Dr. Batycky has a proven track record, and we look forward to her contributions as we execute upon our focused strategy in immunology,” said CEO, Gregory Oakes.
Dr. Alka Batycky will also join the Audit Committee.
About Dr. Alka Batycky
Her expansive skill set includes corporate strategy, regulatory affairs, and research and development. Most recently, Dr. Batycky served as CDO at Finch Therapeutics. Before this, she held executive leadership positions at various biopharmaceutical companies including Ohana Biosciences, Akashi Therapeutics, Warp Drive Bio, and AMAG Pharmaceuticals. She also has held positions of increasing responsibility at CombinatoRx, Synta Pharmaceuticals, Alkermes, and GSK.
Dr. Batycky received her undergraduate and doctoral degrees at the University of London, School of Pharmacy and conducted post-doctoral research at the Medical Research Council, Leicester, UK.
“I am thrilled to join Landos at this pivotal juncture as the Company focuses on advancing the NX-13 clinical program in Ulcerative Colitis,” said Dr. Alka Batycky. “I look forward to working with Landos’ Board and management team to build shareholder value while contributing my scientific and clinical expertise towards improving the lives of patients with inflammatory bowel disease.”
About Landos Biopharma
Landos Biopharma is a clinical-stage biopharmaceutical company focused on developing first-in-class oral therapeutics for patients with autoimmune diseases. Our mission is to create safer and more effective treatments that address the therapeutic gap in the current treatment paradigm.
We have a portfolio of novel targets anchoring two libraries of immunometabolic modulation pathways, including four potentially first-in-class, once-daily, oral therapies targeting eight indications in the immunology space.
We are currently focused on advancing the clinical development of NX-13 in UC. We initiated our NEXUS Phase 2 proof-of-concept trial in April 2023 and expect to report topline results by the fourth quarter of 2024. Source: https://landosbiopharma.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
